Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup

Abstract

Key Points• GO before transplant improves outcome of CBF-AML patients in first relapse.Although core-binding factor-acute myeloid leukemia (CBF-AML) (t[8;21] (range, 16-76). Median first complete remission duration was 12.1 months (range, 2.1-93.6). Overall, second complete remission (CR2) rate was 88%. With a median follow-up from relapse of 3.5 years, the estimated 5-year disease-free survival (DFS) was 50% and 5-year overall survival (OS) was 51%. Older age and shorter first complete remission duration was associated with a shorter OS. Patients treated with GO had similar CR2 rate but significantly higher 5-year DFS (68% vs 42%; P 5 .05) and OS (65% vs 44%; P 5 .02). In multivariate analysis, GO salvage was still associated with a significant benefit in DFS and OS. In the 78 patients who received allogeneic hematopoietic stem cell transplantation in CR2, GO before transplant significantly improved posttransplant DFS and OS without excess of treatment-related mortality. (Blood. 2014;124(8):1312-1319

Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia

“…Patients with t-AML are more prone to a poor prognosis and cytogenetic findings. Core binding factor abnormalities are associated with an improved outcome in patients with AML (39)(40)(41). However, in the present cohort, t (15,17) appeared to have a good effect on the outcome of disease, even in patients with t-AML (42)(43)(44)(45).…”

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

“…Gemtuzumab ozogamicin has been suggested as a drug of interest in CBF-AML therapy, in frontline and as part of salvage therapy, but it has been shown to be associated with increased liver toxicity. 21,22 Allogeneic stem cell transplant in second CR is a standard recommendation in young adults with AML, but it remains a subject of discussion in CBF-AML. 22,23 In conclusion, we suggest that MRD level monitoring by quantitative RT-PCR during follow-up after high-dose cytarabine-based therapy in CBFA-AML should be evaluated in PB every 3 months for up to two years after consolidation completion.…”

Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

“…Patients with higher CIRS scores are considered to be less fit [11]. A retrospective study by Manda et al suggested that higher CIRS score and age greater than 70 years are associated with worse overall survival outcomes [16]. In addition, higher baseline β2-microglobulin and higher Binet stage are also recognized prognostic factors [11, 12, 17, 18] and are thus potential treatment effect modifiers.…”